Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection

October 22, 2012

Treating chronic hepatitis C infection with antiviral drugs could halve the risk of developing the most common form of liver cancer, in some cases, indicates an analysis of the published research in one of the new BMJ Open Editions.

Hepatocellular carcinoma is the most common form of worldwide, accounting for 90 per cent of all primary cases of the disease. Cirrhosis of the liver and infection are among the most important risk factors.

The authors reviewed the published evidence on the use of antiviral therapy—interferon or , or ribavirin, or a combination—in people with infection, to assess its impact, and to see if the level of viral clearance, prompted by the treatment, made any difference.

In some people, helps the body clear the virus; in others an initial response is followed by a relapse a few months later. If treatment succeeds in keeping the virus at bay for 6 months, the chances of relapse are miniscule.

The authors reviewed the data from 8 comparative treatment trials of those whose had resulted in and fibrosis (gristle) or cirrhosis (scarring and limited working capacity) of the liver.

And they also included data from 5 prospective cohort studies, which regularly monitor similar groups of people over the long term to see what happens to them.

In all, more than 3200 people were included in the analysis. Their treatment, which was predominantly interferon, lasted between 6 months and a year, and they were monitored for periods of between 5 and 8 years.

In the trials, a total of 1156 people were treated with antiviral therapy, 81 of whom developed liver cancer; and 1174 were not, 129 of whom developed the disease—equivalent to a reduction in risk of 47 per cent.

Those in whom treatment cleared the virus, long term, were 85 per cent less likely to develop liver cancer compared with those in whom treatment was less effective. Nevertheless this group were still 43 per cent less likely to develop liver cancer.

The observational (cohort) study data also showed that antiviral therapy curbed the risk of liver cancer by around 70 per cent compared with those not given the treatment.

The authors caution that the length of monitoring and the lack of information on death rates could mean that treatment with interferon may simply delay, rather than prevent, liver cancer in infected patients.

But they point out that standard treatment now consists of interferon plus ribavirin, which is deemed more effective, and that the infection tends to be picked up earlier before it has had time to do wreak long term damage.

Explore further: Combination of oral drugs suppresses common type of hepatitis C

More information: Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials, doi:10.1136/bmjopen-2012-001313

Related Stories

Combination of oral drugs suppresses common type of hepatitis C

January 19, 2012
A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.

New compounds show promise against hepatitis C infection

April 12, 2011
Two bioflavonoids, catechin and naringenin, have displayed antiviral activity on tissue culture infected with Hepatitis C.

Recommended for you

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.